Keyword: Chase Pharmaceuticals
Sarepta taps ex-Allergan leader Ingram as CEO, Biogen places Steele in corporate affairs role, Fikry will lead PPD's lab services.
Doug Ingram has become the latest person to take a turn as Sarepta Therapeutics CEO.
Allergan. M&A of an SME biotech. Millions of dollars involved, biobucks down the line. Seem familiar? Well, the co, still paving an independent path forward after not being subsumed by Pfizer in the spring, is at it again, this time buying out Chase Pharma in a $125 million deal.